aromasil has been researched along with Bone Diseases, Metabolic in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becherini, C; Bernini, M; Bianchi, S; Cecchini, S; De Feo, ML; Delli Paoli, C; Desideri, I; Francolini, G; Livi, L; Meattini, I; Nori, J; Orzalesi, L; Saieva, C; Salvestrini, V; Sanchez, L; Scotti, V; Visani, L | 1 |
| Gibson, K; O'Bryant, CL | 1 |
| Geisler, J; Lønning, PE | 1 |
| De Clerck, N; De Schutter, T; Garcia-Segura, LM; Karperien, M; Kremer Hovinga, S; Postnov, AA; van Doorn, J; van Gool, SA; Veiga, SJ; Wit, JM | 1 |
1 trial(s) available for aromasil and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
Topics: Absorptiometry, Photon; Adult; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ibandronic Acid; Letrozole; Middle Aged; Single-Blind Method | 2019 |
3 other study(ies) available for aromasil and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Osteoporosis; Retrospective Studies; Triazoles | 2008 |
Impact of aromatase inhibitors on bone health in breast cancer patients.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Letrozole; Nitriles; Triazoles; Vitamin D | 2010 |
Impaired body weight and tail length gain and altered bone quality after treatment with the aromatase inhibitor exemestane in male rats.
Topics: Androstadienes; Animals; Aromatase Inhibitors; Body Weight; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Growth Plate; Male; Rats; Rats, Wistar; Tail; X-Ray Microtomography | 2010 |